



TEX4542P0501US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application of:) Pyridine, Pyrimidine, Quinoline and
Chengde Wu, et al.) Quinazoline Urotensin-II Receptor Antagonists
Serial No.: 10/783,916)
Filed: February 20, 2004) Group Art Unit: 1614
Examiner:

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Applications
Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313

Sir:

Attached Form PTO/1449A lists referenced which may be considered to be material to the above-identified application by the Patent Examiner. Copies of these references are enclosed. Entry into the record is respectfully requested.

If any additional fee might be required in connection with this matter, please charge our Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER


By Martin L. Katz
Martin L. Katz, Reg. No. 25,011

Date: May 20, 2004


Citicorp Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661-2511
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Patent Applications. Commissioner for Patents, P. O. Box 14540, Alexandria, Virginia 22313 on **May 20, 2004.**

A handwritten signature in cursive script, reading "Rebecca J. Willis", is written over a horizontal line.

Rebecca J. Willis



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/783,916
				Filing Date	February 20, 2004
				First Named Inventor	Chengde Wu, et al
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	2	Attorney Docket No.	TEX4542P0501US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 03/099773 A1	December 4, 2003	Millenium Pharmaceuticals Inc.		
		WO 02/090353 A1	November 14, 2002	Smithkline Beecham Corporation		
		WO 02/089793 A1	November 14, 2002	Smithkline Beecham Corporation		
		WO 02/089740 A2	November 14, 2002	Smithline Beecham Corporation		
		WO 02/090337 A1	November 14, 2002	Smithkline Beecham Corporation		
		WO 02/089785 A1	November 14, 2002	Smithkline Beecham Corporation		
		WO 02/090348 A1	November 14, 2002	Smithkline Beecham Corporation		
		WO 02/089792 A1	November 14, 2002	Smithkline Beecham Corporation		
		WO 2004/026836 A2	April 1, 2004	Actelion Pharmaceutical Ltd.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.